Remembering Dr. Hoseah Waweru: A Beacon of Hope and Inspiration in the Fight Against Psoriasis

It is with a heavy heart and profound sadness that we at the IPC share the news of the passing of Dr. Hoseah Waweru, esteemed President of the International Federation of Psoriasis Associations (IFPA). IPC stands in solidarity with our colleagues at IFPA as we mourn the loss of a remarkable leader and beloved figure in the global fight against psoriasis

Dr. Waweru was more than just a leader; he was a beacon of hope and inspiration. His remarkable ability to combine positive energy, warmth, empathy, and rigorous dedication made him a unique and cherished figure within our community. His wisdom and guidance not only advanced the mission of IFPA but also fostered a spirit of collaboration and unity that has significantly strengthened the bond between our two organizations.

This loss deeply saddens us. Hoseah’s encouragement and support were instrumental in helping many grow in their roles and find their voices in this critical work. His unwavering optimism and focus in the face of challenges inspired all who knew him.

The legacy of Dr. Waweru’s compassion, dedication, and relentless pursuit of a better future for those affected by psoriasis will continue to guide IPC. His contributions have left an indelible mark on the community, and we are committed to honoring his memory by continuing to strive toward the goals he was so passionate about.

In this time of sorrow, our thoughts are with Dr. Waweru’s family, friends, and all at IFPA. We will ensure that his memory is honored, and his spirit is carried forward in our ongoing efforts.

In memory of Dr. Hoseah Waweru, we have included some photos celebrating his life and contributions.

Comments are closed.

[searchwp_search_form engine=blog_search target="/news" var=_blog_search]

Categories

Recent Posts

Six people stand side by side in business attire, smiling at the camera. Behind them, a banner reads IPC International Council 2025 Think Tank Puerto Rico, focused on Psoriasis in Latin America, with colorful designs and sunlight filtering through curtains.

Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors

A large group attends a conference session, with several panelists seated at a table onstage. One attendee stands to ask a question. The IPC (International Psoriasis Council) logo and AAD 2026 appear in the corner.

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research

A man in a suit smiles at the camera next to text that reads, World Psoriasis Experts Give Their Take on Current, Hot, or Controversial Topics like Biologics in Psoriasis Management. EXPERT COMMENTARY.

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026